================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): February 24, 2005

                       ROCKWELL MEDICAL TECHNOLOGIES, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its Charter)

        Michigan                      000-230-661              38-3317208
---------------------------         --------------        ----------------------
(State or other jurisdiction          (Commission             (IRS Employer
    of incorporation)                File Number)          Identification No.)

                30142 Wixom Road, Michigan                        48334
--------------------------------------------------        ----------------------
       (Address of principal executive offices)                (Zip Code)

     Registrant's telephone number, including area code   (248) 960-9009

                                 Not applicable
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 2.02         RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

        On February 24, 2005, the Company issued the press release attached
hereto as Exhibit 99.1, announcing its financial results for the year and
quarter ended December 31, 2004.

ITEM 7.01         REGULATION FD DISCLOSURE.

        On February 24, 2005, the Company issued the press release attached
hereto as Exhibit 99.1, announcing its financial results for the year and
quarter ended December 31, 2004. .

ITEM 9.01         FINANCIAL STATEMENTS AND EXHIBITS

(c)      EXHIBITS.

         The following exhibit is filed with this Form 8-K:

         Exhibit           Description
         -------           -----------

         99.1              Press release, dated February 24, 2005, issued by
                           Rockwell Medical Technologies, Inc.

                                        2


                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                       ROCKWELL MEDICAL TECHNOLOGIES, INC.

Date:  February 24, 2005               By: /s/ Robert L. Chioini
                                           -------------------------------------
                                           Robert L. Chioini
                                           President and Chief Executive Officer

                                        3


                                  EXHIBIT INDEX

Exhibit           Description
-------           -----------

99.1              Press release, dated February 24, 2005, issued by
                  Rockwell Medical Technologies, Inc.